

12 **EUROPEAN PATENT APPLICATION**

21 Application number: 85113733.1

51 Int. Cl.<sup>4</sup>: **C 12 N 15/00**  
**C 12 N 1/16**  
**/(C12N1/16, C12R1:84)**

22 Date of filing: 29.10.85

30 Priority: 30.10.84 US 666579

43 Date of publication of application:  
 04.06.86 Bulletin 86/23

64 Designated Contracting States:  
 AT BE CH DE FR GB IT LI LU NL SE

71 Applicant: **PHILLIPS PETROLEUM COMPANY**  
 5th and Keeler  
 Bartlesville Oklahoma 74004(US)

72 Inventor: **Stroman, David Womack**  
 2504 SW Centre Rd.  
 Bartlesville Oklahoma 74006(US)

72 Inventor: **Cregg, James Michael**  
 6225 Via Regla  
 San Diego California 92122(US)

72 Inventor: **Sperl, George T.**  
 906 Taylor Drive  
 Gurnee Illinois 60031(US)

72 Inventor: **Harpold, Michael Miller**  
 1341 29th Street  
 San Diego California 92102(US)

74 Representative: **Dost, Wolfgang, Dr.rer.nat.,**  
 Dipl.-Chem. et al,  
 Patent- und Rechtsanwälte  
 Bardehle-Pagenberg-Dost-Altenburg & Partner Postfach  
 86 06 20  
 D-8000 München 86(DE)

54 Transformation of yeasts of the genus *pichia*.

57 Process for transforming yeast strains of the genus *Pichia* is disclosed. Novel yeast strains of the genus *Pichia* which can be transformed with recombinant DNA material are also disclosed. In addition, a method for isolating functional genes and other functional DNA sequences from yeast strains of the genus *Pichia* is described.




FIG. 4

TRANSFORMATION OF YEASTS OF THE GENUS *PICHIA*Background

This invention relates to the field of recombinant DNA technology. In one of its aspects, the invention relates to novel yeast strains. In another aspect, the invention  
5 relates to processes for transforming yeast strains with recombinant DNA material.

Up to now, commercial efforts employing recombinant DNA technology for producing various polypeptides have centered on *Escherichia coli* as a host organism. However, in  
10 some situations *E. coli* may prove to be unsuitable as a host. For example, *E. coli* contains a number of toxic pyrogenic factors that must be eliminated from any polypeptide useful as a pharmaceutical product. The efficiency with which this purification can be achieved will, of course, vary with the  
15 particular polypeptide. In addition, the proteolytic activities of *E. coli* can seriously limit yields of some useful products. These and other considerations have led to increased interest in alternative hosts, in particular, the use of eukaryotic organisms for the production of polypeptide  
20 products is appealing.

The availability of means for the production of polypeptide products in eukaryotic systems, e.g., yeast, could provide significant advantages relative to the use of prokaryotic systems such as *E. coli* for the production of  
25 polypeptides encoded by recombinant DNA. Yeast has been employed in large scale fermentations for centuries, as compared to the relatively recent advent of large scale *E.*

coli fermentations. Yeast can generally be grown at higher cell densities than bacteria and are readily adaptable to continuous fermentation processing. In fact, growth of yeast such as *Pichia pastoris* to ultra-high cell densities, i.e., cell densities in excess of 100 g/L, is disclosed by Wegner in U.S. 4,414,329 (assigned to Phillips Petroleum Co.). Additional advantages of yeast hosts include the fact that many critical functions of the organism, e.g., oxidative phosphorylation, are located within organelles, and hence not exposed to the possible deleterious effects of the organism's production of polypeptides foreign to the wild-type host cells. As a eukaryotic organism, yeast may prove capable of glycosylating expressed polypeptide products where such glycosylation is important to the bioactivity of the polypeptide product. It is also possible that as a eukaryotic organism, yeast will exhibit the same codon preferences as higher organisms, thus tending toward more efficient production of expression products from mammalian genes or from complementary DNA (cDNA) obtained by reverse transcription from, for example, mammalian mRNA.

The development of poorly characterized yeast species as host/vector systems is severely hampered by the lack of knowledge about transformation conditions and suitable vectors. In addition, auxotrophic mutations are often not available, precluding a direct selection for transformants by auxotrophic complementation. If recombinant DNA technology is to fully sustain its promise, new host/vector systems must be devised which facilitate the manipulation of DNA as well as optimize expression of inserted DNA sequences so that the desired polypeptide products can be prepared under controlled conditions and in high yield.

#### Objects of the Invention

An object of our invention, therefore, is the transformation of yeast of the genus *Pichia*.

Another object of our invention is a host of the genus *Pichia* suitable for transformation with recombinant DNA material.

5 These and other objects of the invention will become apparent from the disclosure and claims herein provided.

#### Statement of the Invention

10 In accordance with the present invention, we have developed a process for the transformation of yeast cells of the genus *Pichia*. By the practice of the transformation process of the present invention, DNA sequences can be introduced into host cells of the genus *Pichia*, allowing *Pichia* to be employed as a host system for the production of polypeptide product in yeast.

15 Further, in accordance with the present invention, novel strains of microorganisms of the genus *Pichia* are provided. These novel strains are useful as hosts for the introduction of recombinant DNA material into yeast.

20 In accordance with another embodiment of the invention, the novel strains of microorganisms of the genus *Pichia* are employed in a process for the isolation of functional genes and other functional DNA sequences from yeast strains of the genus *Pichia*.

#### Brief Description of the Drawings

25 Figure 1 is a restriction map of plasmid pYA2.  
Figure 2 is a restriction map of plasmid YEp13.  
Figure 3 is a restriction map of plasmid pYA4.  
Figure 4 is a restriction map of plasmid pYJ30.  
Figure 5 is a restriction map of plasmid pYJ32.  
30 Figure 6 is a restriction map of plasmid pSAOH5.

The following abbreviations are used throughout this application to represent the restriction enzymes employed:

	<u>Abbreviation</u>	<u>Restriction Enzyme</u>
	B	<i>Bam</i> HI
	B <sub>2</sub>	<i>Bgl</i> II
	H <sub>3</sub>	<i>Hind</i> III
5	Nr	<i>Nru</i> I
	Ps	<i>Pst</i> I
	R <sub>1</sub>	<i>Eco</i> RI
	R <sub>5</sub>	<i>Eco</i> RV
	S	<i>Sal</i> I
10	Sm	<i>Sma</i> I
	Sp	<i>Sph</i> I
	S <sub>3</sub>	<i>Sau</i> 3AI
	Xh	<i>Xho</i> I

The convention employed in the Figures is to show in parentheses a restriction enzyme site which was used for construction of the DNA sequence but was destroyed upon ligation of the construct.

#### Detailed Description of the Invention

In accordance with the present invention, a transformation procedure for the introduction of recombinant DNA material into host cells of the genus *Pichia* is provided.

Further in accordance with the present invention, novel yeast strains of the genus *Pichia* are provided which are useful as hosts for the introduction of recombinant DNA material.

In accordance with another embodiment of the invention, a method is provided for the isolation of functional genes and other functional DNA sequences from the genome of yeasts of the genus *Pichia*.

#### Development of *Pichia pastoris* Transformation System

The transformation of *Pichia pastoris* has not been previously described. The experimental procedures for transformation of *Pichia pastoris* are presented in greater detail below (Example III). In order to develop a transformation system for *P. pastoris*, the auxotrophic mutant

0183070

GS115 (NRRL Y-15851) was isolated and determined to be defective in the histidine pathway in that the strain has no detectable histidinol dehydrogenase activity. (See assay procedure in Example II).

5           Those of skill in the art recognize that mutation frequencies can be increased in a variety of ways, such as, for example, by subjecting exponentially growing cells to the action of a variety of mutagenic agents, such as, for example, N-methyl-N'-nitro-N-nitrosoguanidine, ethyl  
10 methanesulfonate, ultraviolet irradiation and the like. Isolation and identification of mutant strains defective in a specific metabolic pathway can be accomplished by determining the nutrient or nutrients required by the strain for growth as detailed, for example, in Example I. The specific gene  
15 and gene product in which a mutant strain is defective can then be determined by identifying the enzymatic activity which is absent, as detailed, for example, in Example II.

          Yeast strains of the genus *Pichia*, and especially mutant *Pichia* strains of the invention can be transformed by  
20 enzymatic digestion of the cell walls to give spheroplasts; the spheroplasts are then mixed with the transforming DNA and incubated in the presence of calcium ions and polyethylene glycol, then regenerated in selective growth medium. The transforming DNA includes the functional gene in which the  
25 host strain is defective, thus only transformed cells survive on the selective growth medium employed.

          To prepare *Pichia* spheroplasts, the cells are first contacted with a sulfhydryl group reducing agent, such as, for example, dithiothreitol or  $\beta$ -mercaptoethanol. An example  
30 of a specific solution containing a sulfhydryl group reducing agent is the dithiothreitol in SED buffer described in the Examples. Enzymatic digestion of the cell walls can then be accomplished by contacting the strain to be transformed with any of the many cell wall degrading reagents known to those  
35 of skill in the art, such as for example Zymolyase (Miles Laboratories), Glusulase (Endo Laboratories), and the like. Although a wide variety of temperatures, contact times and

dosage levels are operable, generally, when using, for example, Zymolyase 60,000 (60,000 units/g) about 10 up to about 100  $\mu$ g of cell wall degrading reagent per 10 mL of cell suspension are employed for spheroplast formation.

5 Preferably about 40-50  $\mu$ g of Zymolyase 60,000 per 10 mL of cell suspension is employed. Temperature is generally maintained at about 25°C or above, but less than about 35°C. Preferably, temperature is maintained at about 30°C. Contact time is generally at least about 15 minutes and usually no  
10 greater than about 60 minutes. While many buffered media are suitable, it is essential that cells to be converted to spheroplasts be suspended in a buffer which is iso-osmotic with the cells, such as, for example, SCE buffer (sorbitol/citrate/EDTA; see Examples for recipe).

15 The spheroplasts can be transformed by contact with virtually any amount of recombinant DNA material. Generally, at least about 0.01  $\mu$ g of transforming DNA per 100  $\mu$ L of spheroplast containing solution (containing between about  $1-3 \times 10^7$  spheroplasts per 100  $\mu$ L) are employed. Where only  
20 small amounts of recombinant DNA material are available, sonicated *E. coli* DNA can be used to supplement the amount of available DNA, thereby improving transformation frequencies by minimizing the handling losses of recombinant DNA material during experimental manipulation.

25 Transformed spheroplasts are then treated under cell wall regenerating conditions. Cell wall regenerating conditions comprise adding a sample containing transformed spheroplasts to melted regeneration agar maintained at about 40-60°C. A typical regeneration agar provides a balanced  
30 osmotic media and comprises:

sorbitol	about 1 M
dextrose	about 0.1 M
yeast nitrogen base	about 7 g/L
Bacto-agar	about 3%

35 The transformed spheroplasts in melted regeneration agar are poured over a bottom layer of regeneration agar and then incubated at about 25-35°C for about 3-10 days.

*Pichia pastoris* NRRL Y-15851 (GS115) has been transformed with a number of plasmids. Several of these plasmids are novel and have therefore been made available to the public by deposition with the Northern Regional Research Center in Peoria, Illinois. Plasmids and their accession numbers are tabulated below (all plasmids have been deposited in an *E. coli* host).

	<u>Plasmid</u>	<u>Inventor strain designation</u>	<u>NRRL accession number</u>
10	pYA2	LE392-pYA2	B-15874
	pYJ30	LE392-pYJ30	B-15890
	pYJ32	LE392-pYJ32	B-15891
	pSAOH5	MC1061-pSAOH5	B-15862

Also used to transform GS115 was plasmid pYA4, which is derived from the *S. cerevisiae* - *E. coli* shuttle vector YEpl3 (available from ATCC #37115; see Figure 2). Thus, plasmid pYA4 is YEpl3 plus a 6.0 kbp *Sau*3A partial digestion fragment of *Pichia pastoris* chromosomal DNA which includes the *HIS4* gene (see Figure 3) ligated into the unique *Bam*HI site of YEpl3.

Plasmid pYA2 (see Figure 1) contains pBR325 DNA sequences and a 9.3 kbp *S. cerevisiae* *Pst*I fragment which includes the *S. cerevisiae* *HIS4* gene. It was surprisingly found that the *S. cerevisiae* *HIS4* gene in plasmid pYA2 functioned in *Pichia*. An additional surprising observation was the fact that pYA2, which transforms *S. cerevisiae* at low frequency by integrative recombination, transformed *Pichia* at high frequency and was maintained as an extrachromosomal element in NRRL Y-15851 over a number of generations of growth.

Plasmid pYJ30, shown in Figure 4, has pBR322 DNA sequences, a 2.7 kbp *Bgl*III fragment of *Pichia* chromosomal DNA which has the *Pichia* *HIS4* gene and a 164 bp *Taq*I fragment of *Pichia* chromosomal DNA which has autonomous replication sequence activity (PARS1). This plasmid has also been used



to transform NRRL Y-15851 (GS115), and transformation occurs at high frequency. This plasmid is useful for introducing recombinant DNA material into a *Pichia* host. For example, plasmid pSAOH5 (see Figure 6) is derived from this plasmid by  
5 insertion of the *E. coli* LacZ gene and the alcohol oxidase regulatory region at the unique R<sub>1</sub> site of pYJ30. Plasmid pSAOH5 is shown in Example IV below to be capable of producing a polypeptide product not native to the host cell in *Pichia pastoris*.

10 Plasmid pYJ32, shown in Figure 5, is similar to pYJ30, except the autonomous replication activity is provided by PARS2, a 385 bp *Taq*I fragment of *Pichia* chromosomal DNA. This plasmid is also capable of transforming *Pichia pastoris* NRRL Y-15851 at high frequencies.

15 The transformation of yeast strains of the genus *Pichia*, as demonstrated herein, makes possible the introduction of recombinant DNA material into yeast hosts. As further detailed in the examples which follow, transformed yeast strains of the genus *Pichia* are useful, for example,  
20 for the production of polypeptide products by a yeast host.

In accordance with another embodiment of the present invention, there is provided a method for isolation of functional genes and other functional DNA sequences from yeast strains of the genus *Pichia*. For the isolation of  
25 functional genes, the method comprises complementation of a defective *Pichia pastoris* strain with cloned fragments of *Pichia* chromosomal DNA, selection of transformed strains which survive selective growth conditions, wherein the selective growth conditions comprise minimal media absent the  
30 gene product required by the defective host strain for growth, isolation and recovery of *Pichia* DNA inserts from the plasmids contained in the selected transformed strains. For example, one could isolate the *Pichia* LEU2 gene by transforming a *leu2 P. pastoris* mutant with a library of  
35 *Pichia* chromosomal DNA and selecting for transformed strains which survive in the absence of leucine supplementation of the media. Similarly, one could isolate the *Pichia* ARG4 gene

0183070

by transforming an appropriate *P. pastoris* mutant with a library of *Pichia* chromosomal DNA and proceeding as above, except the selection media would be absent histidine or arginine supplementation, respectively.

5           Those of skill in the art recognize that other functional DNA sequences can be isolated using the transformation system of the present invention. Such sequences include:

10           autonomous replication sequences (ARSSs),  
            centromeric sequences (CENs)  
            chromosomal termini (telomeres),  
            promoters and regulatory sequences,  
            transcription and translation terminators, and the like.

15

EXAMPLES

The buffers and solutions employed in the following examples have the compositions given below:

1M Tris buffer           121.1 g Tris base in 800 mL of H<sub>2</sub>O;  
                          adjust pH to the desired value by  
20                        adding concentrated (35%) aqueous HCl;  
                          allow solution to cool to room  
                          temperature before final pH adjustment;  
                          dilute to a final volume of 1L.

TE buffer               1.0 mM EDTA  
25                        in 0.01 M (pH 7.4) Tris buffer

YPD Medium             1% Bacto-yeast extract  
                          2% Bacto-peptone  
                          2% Dextrose

30           SD Medium           6.75 g yeast nitrogen base  
                          without amino acids (DIFCO)  
                          2% Dextrose  
                          in 1 L of water

SED	1 <u>M</u> Sorbitol
	25 <u>mM</u> EDTA
	50 <u>mM</u> DTT
5	SCE Buffer
	9.1 g Sorbitol
	1.47 g Sodium citrate
	0.168 g EDTA
	50 mL H <sub>2</sub> O
	--pH to 5.8 with HCl
10	CaS
	1 <u>M</u> Sorbitol
	10 <u>mM</u> CaCl <sub>2</sub>
	--filter sterilize
	PEG Solution
	20% polyethylene glycol-3350
	10 <u>mM</u> CaCl <sub>2</sub>
	10 <u>mM</u> Tris-HCl (pH 7.4)
15	--filter sterilize
	SOS
	1 <u>M</u> Sorbitol
	0.3x YPD medium
	10 <u>mM</u> CaCl <sub>2</sub>
20	MM (minimal medium)
	0.875 g KH <sub>2</sub> PO <sub>4</sub>
	0.125 g K <sub>2</sub> HPO <sub>4</sub>
	1.0 g (NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub>
	0.5 g MgSO <sub>4</sub> ·7H <sub>2</sub> O
	0.1 g NaCl
	0.05 mg FeCl <sub>3</sub> ·6H <sub>2</sub> O
25	0.07 mg ZnSO <sub>4</sub> ·7H <sub>2</sub> O
	0.01 mg H <sub>3</sub> BO <sub>3</sub>
	0.01 mg CuSO <sub>4</sub> ·5H <sub>2</sub> O
	0.01 mg KI
	0.1 g CaCl <sub>2</sub> ·2H <sub>2</sub> O
30	--per liter of sterile H <sub>2</sub> O
	MM "minus"
	MM formulation without (NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub>

	Citrate buffer	9.79 g sodium citrate 3.2 g citric acid ---dilute to 500 mL with H <sub>2</sub> O ---adjust to pH 5.5 with 1 <u>N</u> NaOH
5	Nystatin solution	4.4 mg nystatin (5680 Units/mg) 1 mL dimethyl formamide ---dilute to 10 mL with water
	E Buffer	50 <u>mM</u> Tris-HCl(pH 7.4) 0.01 <u>mM</u> histidinol
10		50 <u>mM</u> MgSO <sub>4</sub> 1 <u>mM</u> DTT
	Vitamin Mix	p-aminobenzoic acid 50 mg/100mL p-hydroxybenzoic acid 50 riboflavin 25
15		pantothenate 50 B <sub>12</sub> 1 folic acid 50 pyridoxine 50 biotin 5
20		thiamine 10 nicotinic acid 50 inositol 2000

The following abbreviations are used throughout the example, with the following meaning:

25	NTG	N-methyl-N'-nitro-N-nitrosoguanidine
	DTT	dithiothreitol
	NAD	nicotinamide adenine dinucleotide
	SDS	sodium dodecyl sulfate
	ala	alanine
30	arg	arginine
	asn	asparagine
	asp	aspartic acid

	cys	cysteine
	glu	glutamic acid
	gln	glutamine
	gly	glycine
5	his	histidine
	ile	isoleucine
	leu	leucine
	lys	lysine
	met	methionine
10	phe	phenylalanine
	pro	proline
	ser	serine
	thr	threonine
	trp	tryptophan
15	tyr	tyrosine
	val	valine

#### EXAMPLE I

#### Isolation of Auxotrophic Mutants

##### A. Pichia Mutagenesis

20 Culture of a selected yeast strain, such as for  
example, *Pichia pastoris* NRRL Y-11430, was inoculated into  
100 mL of YPD broth and incubated at 30°C on a shaker for  
about 12-20 hrs. About 40 mL of the resulting culture were  
spun down at about 2,000 g for 5 minutes. The cells were  
25 then washed twice with 40 mL aliquots of sterile 0.1 M  
citrate buffer (pH 5.5). Washed cells were resuspended in 36  
mL of sterile citrate buffer, then treated with 4 mL of NTG  
solution containing 5 mg of NTG per mL---thus giving a final  
NTG concentraton of 500 µg/mL. Cells in the presence of NTG  
30 were allowed to stand for about 30 minutes at room  
temperature without agitation.

NTG was then removed by washing the cells twice  
with 40 mL aliquots of sterile deionized water. Sufficient  
YPD medium was used to resuspend washed cells, which were  
35 then transferred to a flask and total volume brought up to

100 mL with additional YPD. These mutagenized cells were then incubated at 30°C on a shaker for about 48 hours.

After incubation, about 40 mL of the yeast containing solution were spun down at 2,000 g for 5 minutes.  
5 The cell pellet was washed twice with 40 mL aliquots of sterile, deionized water, then suspended in 40 mL of MM "minus" media plus 1% glucose carbon source and 5 µg biotin and incubated at 30°C on a shaker for 12-20 hours.

B. Nystatin enrichment

10 Five mL of the above culture grown on glucose was used to inoculate 100 mL of "restricted media". Restricted media comprises the MM formulation plus carbon source (typically 1% glucose), vitamin/amino acid supplementation as appropriate (such as the "vitamin mix" referred to above),  
15 except no supplementation is provided for the metabolite produced by the biosynthetic pathway in which a defect is sought. For example, where a leucine auxotroph is desired, no leucine supplementation will be provided. The inoculum in restricted media was incubated at 30°C in a shake flask and  
20 monitored periodically on a Klett-Summerson photoelectric colorimeter equipped with a 500-570 millimicron green filter. Incubation was continued until the scale reading (which is proportional to optical density) has increased 20-30% with respect to the original scale reading.

25 When the scale reading had increased as desired, the solution was treated with 1 mL of Nystatin solution, giving a Nystatin content of about 25 units/mL in the solution. The Nystatin-treated solution was incubated at 30° for 90 minutes without agitation, at which time 40 mL of the  
30 solution was spun down and the cells washed twice with 40 mL aliquots of deionized water. Washed cells were then diluted as appropriate in order to obtain about 100-150 colonies per plate. Colonies were plated on mutant growth media which consisted of MM media, carbon source (typically 1% glucose),  
35 5µg biotin and supplementation for any metabolite produced by

the biosynthetic pathway in which the mutational defect is sought.

The colonies plated on mutant growth media were replica plated onto media formulation absent the metabolite supplementation. The original and replica plates were incubated at 30° for at least 48 hours. Those colonies that grew on the original plate (on mutant growth media) but not on the replica plates were selected for further characterization.

The auxotrophic mutants selected were transferred to metabolic pool plates and incubated at 30°C for at least 48 hours in order to determine in which pathway(s) mutational defects existed.

Pool plates were prepared by dissolving 10mg/mL of the L-isomer of each of 5 different amino acids, as follows:

	1	2	3	4	5
6	gly	asn	cys	met	gln
7	his	leu	ile	val	lys
8	phe	tyr	trp	thr	pro
20	9	glu	ser	ala	asp
				arg	

Thus, plate 1 contains 10 mg/mL each of glycine, histidine, phenylalanine and glutamic acid; plate 2 contains 10 mg/mL each of asparagine, leucine, tyrosine and serine, and so on. A tenth plate was prepared by dissolving 1 g of Casamino acids in 1 L of sterile water.

An aliquot of 250 µL of each of amino acid pools 1-10 was applied to plates containing minimal media plus 1% glucose, and the plates allowed to dry overnight.

The mutational defect of a given mutant can be determined by inspection of the growth pattern on the various pool plates. Thus GS115, a mutant defective in the histidine pathway, grew only on plates 1, 7 and 10, but not on the other pool plates which do not provide histidine supplementations. Similarly, GS190, a mutant defective in

0183070

0183070

0183070

0183070

0183070

- 0183070

0183070

0183070

0183070



harvested by centrifugation and the cell pellet stored at -20°C.

The next step was to prepare a cell extract from the culture. Approximately 1 gram (wet weight) of cells was washed 2 times in 10 mL of cold H<sub>2</sub>O (4°C) and resuspended in 0.83 mL of cold E buffer. To rupture the cells, the sample was passed through an Aminco French pressure cell which had a 0.374 inch diameter piston using an Aminco French press at 20,000 PSI. The pressure cell was held on ice until use and the procedure was performed in a cold room (4°C). To monitor cell breakage, a 10 µL sample was added to 10 mL of H<sub>2</sub>O and its OD<sub>600</sub> determined and compared to an identically prepared control sample which had not been passed through the pressure cell. If the optical density of the treated sample was greater than 50% of the control, the sample was subjected to the disruption procedure a second time. The extract was then centrifuged in a Beckman SW50.1 rotor at 35,000 rpm and 4°C for 30 minutes to remove cell debris. The supernatant was removed, mixed with an equal volume of 4°C glycerol and stored at -20°C.

The concentration of total protein in an extract was estimated using the Bio-Rad Laboratories protein assay method. For this the Bio-Rad Dye Reagent Concentrate was diluted with four volumes of deionized H<sub>2</sub>O and filtered through Whatman 3MM paper. A standard concentration curve was then prepared by adding 3, 10, 30, and 100 µg of bovine serum albumin (BSA) in 100 µL E buffer with 50% glycerol to a set of 13x100 mm glass tubes, each of which contained 2.5 mL of the dye reagent. The samples were mixed and held at room temperature for 5 minutes and their optical densities at 595 nm determined. For analyses of the extract, 3, 10, and 30 µL samples were brought to 100 µL with a solution containing E buffer and 50% glycerol and assayed for protein content as described above. A protein concentration value for each extract was then interpolated using the BSA concentration curve.

The final step in the histidinol dehydrogenase activity assay was to measure histidinol dehydrogenase activity in an extract by measuring spectrophotometrically the reduction of NAD which occurs in the presence of histidinol. For each extract to be assayed, a reaction mixture which contained 3 mL of H<sub>2</sub>O, 0.5 mL of 0.5 M glycine (pH 9.4), 0.5 mL of 5 mM MnCl<sub>2</sub> and 0.5 mL of 0.1 M NAD was prepared on ice. A 2.25 mL aliquot of this mix was added to 2 13x100 mm glass tubes which were on ice. A sample which contained between 50 to 500 µg of protein was added to each of the tubes and the tubes were incubated at 25°C. After 5 minutes the reaction was started by the addition of 0.25 mL of 0.15 M histidinol to one tube and 0.25 mL of H<sub>2</sub>O to the other. The optical density of each reaction tube at 340 nm was determined at times of 0.0, 0.5, 1.0 and 2.0 hours. As controls, extracts prepared from *Pichia pastoris* NRRL Y-11430 and *Saccharomyces cerevisiae* 5799-4D (NRRL Y-15859) were assayed in parallel. The net OD<sub>340</sub> value for each time point was determined by subtracting the value obtained from the sample incubated without histidinol from the value obtained from the sample incubated with histidinol.

While *Pichia pastoris* NRRL Y-11430, a wild type strain requiring no amino acid supplementation, gave an OD<sub>340</sub> of about 0.25, 0.38 and 0.75 at 0.5, 1.0 and 2.0 hours, respectively, the control *his4C* mutant (*S. cerevisiae* NRRL Y-15859) gave an OD<sub>340</sub> of essentially zero at all time points. One such *Pichia pastoris* mutant, designated GS115 and deposited with the Northern Regional Research Center having the accession number NRRL Y-15851, similarly gave an OD<sub>340</sub> of essentially zero at all time points. Consistent with the mutant genotype nomenclature employed for *S. cerevisiae*, GS115 has been designated as a *his4C* mutant strain.

*Pichia pastoris* Transformation ProcedureA. Cell Growth

1. Inoculate a colony of *Pichia pastoris* GS115 (NRRL Y-15851) into about 10 mL of YPD medium and shake culture at 30°C for 12-20 hrs.
2. After about 12-20 hrs., dilute cells to an OD<sub>600</sub> of about 0.01-0.1 and maintain cells in log growth phase in YPD medium at 30°C for about 6-8 hrs.
3. After about 6-8 hrs, inoculate 100 mL of YPD medium with 0.5 mL of the seed culture at an OD<sub>600</sub> of about 0.1 (or equivalent amount). Shake at 30°C for about 12-20 hrs.
4. Harvest culture when OD<sub>600</sub> is about 0.2-0.3 (after approximately 16-20 hrs) by centrifugation at 1500 g for 5 minutes.

B. Preparation of Spheroplasts

1. Wash cells once in 10 mL of sterile water. (All centrifugations for steps 1-5 are at 1500 g for 5 minutes.)
2. Wash cells once in 10 mL of freshly prepared SED.
3. Wash cells twice in 10 mL of sterile 1 M Sorbitol.
4. Resuspend cells in 10 mL SCE buffer.
5. Add 5-10 µL of 4 mg/mL Zymolyase 60,000 (Miles Laboratories). Incubate cells at 30°C for about 30-60 minutes.

Since the preparation of spheroplasts is a critical step in the transformation procedure, one should monitor spheroplast formation as follows: add 100 µL aliquots of cells to 900 µL of 5% SDS and 900 µL of 1 M Sorbitol before or just after the addition of zymolyase and at various times during the incubation period. Stop the incubation at the point where cells lyse in SDS but not in sorbitol (usually between 30 and 60 minutes of incubation).

6. Wash spheroplasts twice in 10 mL of sterile 1 M Sorbitol by centrifugation at 1000 g for 5-10 minutes. (The time and speed for centrifugation may vary; centrifuge enough to pellet spheroplasts but not so much that they rupture from the force.)
7. Wash cells once in 10 mL of sterile CaS.
8. Resuspend cells in total of 0.6 mL of CaS.

C. Transformation

1. Add DNA samples (up to 20  $\mu$ L volume) to 12 X 75 mm sterile polypropylene tubes. (DNA should be in water or TE buffer; for maximum transformation frequencies with small amounts of DNA, it is advisable to add about 1  $\mu$ L of 5 mg/mL sonicated *E. coli* DNA to each sample.)
2. Add 100  $\mu$ L of spheroplasts to each DNA sample and incubate at room temperature for about 20 minutes.
3. Add 1 mL of PEG solution to each sample and incubate at room temperature for about 15 minutes.
4. Centrifuge samples at 1000 g for 5-10 minutes and decant PEG solution.
5. Resuspend samples in 150  $\mu$ L of SOS and incubate for 30 minutes at room temperature.
6. Add 850  $\mu$ L of sterile 1 M Sorbitol and plate aliquots of samples as described below.

D. Regeneration of Spheroplasts

1. Recipe for Regeneration Agar Medium:
- a. Agar-Sorbitol- 9 g Bacto-agar, 54.6 g Sorbitol, 240 mL H<sub>2</sub>O, autoclave.
- b. 10X Glucose- 20 g Dextrose, 100 mL H<sub>2</sub>O, autoclave.
- c. 10X SC- 6.75 g Yeast Nitrogen Base without amino acids, 100 mL H<sub>2</sub>O, autoclave. (Add any desired amino acid or nucleic acid up to a concentration of 200  $\mu$ g/mL before or after autoclaving.)
- d. Add 30 mL of 10X Glucose and 30 mL of 10X SC to the melted Agar-Sorbitol solution to give a total of 300 mL. Add

0.6 mL of 0.2 mg/mL biotin and any other desired amino acid or nucleic acid to a concentration of 20 µg/mL. Hold melted Regeneration Agar at 55-60°C.

2. Plating of Transformation Samples:

5            Pour bottom agar layer of 10 mL Regeneration Agar per plate at least 30 minutes before transformation samples are ready. Distribute 10 mL aliquots of Regeneration Agar to tubes in a 45-50°C bath during the period that transformation samples are in SOS. Add aliquots of transformation samples  
10 described above to tubes with Regeneration Agar and pour onto bottom agar layer of plates. Add a quantity of each sample to 10 mL aliquots of melted Regeneration Agar held at 45-50°C and pour each onto plates containing a solid 10 mL bottom agar layer of Regeneration Agar.

15            3. Determination of Quality of Spheroplast Preparation:

Remove 10 µL of one sample and dilute 100 times by addition to 990 µL of 1 M Sorbitol. Remove 10 µL of the 100 fold dilution and dilute an additional 100 times by addition to a second 990 µL aliquot of 1 M Sorbitol. Spread plate 100  
20 µL of both dilutions on YPD agar medium to determine the concentration of unspheroplasted whole cells remaining in the preparation. Add 100 µL of each dilution to 10 mL of Regeneration Agar supplemented with 40 µg/mL histidine to determine total regeneratable spheroplasts. Good values for  
25 a transformation experiment are  $1-3 \times 10^7$  total regeneratable spheroplasts/mL and about  $1 \times 10^3$  whole cells/mL.

4. Incubate plates at 30°C for 3-5 days.

EXAMPLE IV

Production of β-Galactosidase in *Pichia pastoris*

30            The production of β-galactosidase in transformed *Pichia pastoris* demonstrates the ability of yeast of the genus *Pichia* to be employed as a host/vector system for the production of polypeptide products. *Pichia pastoris* GS115 (NRRL Y-15851) was transformed with plasmid pSAOH5 (see

Figure 6) and grown up in minimal medium containing 0.5  $\mu\text{g/mL}$  of biotin and 0.1% glucose at 30°C until they reached stationary phase. The cells were then shifted to minimal medium containing 0.5  $\mu\text{g/mL}$  of biotin and 0.5% methanol and grown for about 3-5 generations at 30°C. After this initial growth on methanol, cells were shifted to fresh minimal media containing 0.5  $\mu\text{g/mL}$  biotin and 0.2% methanol as carbon source. The cells were incubated at 30°C for about 80 hours, with samples periodically drawn to determine alcohol oxidase and  $\beta$ -galactosidase levels.

The first sample drawn, immediately after the cells were shifted to the growth medium, analyzed for over 500 units of alcohol oxidase and over 1100 units of  $\beta$ -galactosidase. Assay procedures employed are detailed in the appendix.

These results demonstrate the utility of of *Pichia pastoris* as a host/vector system for the production of gene products in yeast. The plasmid employed to transform the host, plasmid pSAOH5, is a *Pichia* plasmid which codes for the production of  $\beta$ -galactosidase under the control of a methanol responsive regulatory region. The transformed strain used for this demonstration has been deposited with the Northern Regional Research Center and is available to the public under the accession number NRRL Y-15853.

The examples have been provided merely to illustrate the practice of our invention and should not be read so as to limit the scope of our invention or the appended claims in any way. Reasonable variation and modification, not departing from the essence and spirit of our invention, are contemplated to be within the scope of patent protection desired and sought.

APPENDIX

0183070

Alcohol Oxidase Assay

The alcohol oxidase activity for reaction with methanol was determined by the following assay procedure (dye-peroxidase method). A dye-buffer mixture was prepared by mixing 0.1 mL of an o-dianisidine solution (1 weight % o-dianisidine in water) with 12 mL of aerated 0.1 M sodium phosphate buffer (pH 7.5). The assay mixture was prepared with 2.5 mL of the dye-buffer mixture, 50  $\mu$ L of methanol, 10  $\mu$ L of a peroxidase solution (1 mg of horse-radish peroxidase-Sigma, Type II), and 25  $\mu$ L of the alcohol oxidase solution. The assay mixture was maintained at 25°C in a 4x1x1 cm cuvette and the increase in absorbance by the dye at 460 nm was recorded for 2 to 4 minutes. The enzyme activity was calculated by

$$\text{Activity } (\mu \text{ mole/min/mL or Enzyme Units/mL}) = \frac{\Delta A}{\text{min}} \times 11.5$$

wherein 11.5 is a factor based on a standard curve prepared with known aliquots of  $\text{H}_2\text{O}_2$  and  $\Delta A$  is the change in absorbance during the experimental interval.

 $\beta$ -Galactosidase Assay

$\beta$ -Galactosidase was determined as follows:

## A. Solutions required:

<u>Z-buffer:</u>			<u>Final concentration</u>
	Na <sub>2</sub> HPO <sub>4</sub> • 7H <sub>2</sub> O	16.1 g	0.06 <u>M</u>
	NaH <sub>2</sub> PO <sub>4</sub>	5.5 g	0.04 <u>M</u>
5	KCl	0.75 g	0.01 <u>M</u>
	MgSO <sub>4</sub> • 7H <sub>2</sub> O	0.246 g	0.001 <u>M</u>
	2-mercaptoethanol	2.7 mL	0.05 <u>M</u>
fill up to 1L; pH should be 7			

O-Nitrophenyl-β-D-galactoside (ONPG):

- 10 Dissolve 400 mg ONPG (Sigma N-1127) in 100 mL of distilled water to make a 4 mg/mL ONPG solution.

## B. Assay Procedure:

1. Withdraw an aliquot from the culture medium (0.1-0.5 OD<sub>600</sub> of yeast cells), centrifuge and wash cell pellet with water.
- 15 2. Add 1 mL of Z buffer to the cell pellet, 30 μL of CHCl<sub>3</sub> and 30 μL of 0.1% SDS, vortex, incubate 5 minutes at 30°C.
3. Start reaction by adding 0.2 mL of ONPG (4 mg/mL), vortex.
- 20 4. Stop reaction by adding 0.5 mL of a 1 M Na<sub>2</sub>CO<sub>3</sub> solution at appropriate time points A<sub>420</sub><1).
5. Read absorbance of supernatant at 420 nm.

C. Calculation of β-galactosidase Units:

- 25 1 U = 1 nmole of orthonitrophenol (ONP) formed per minute at 30°C and a pH 7.
- 1 nmole of ONP has an absorbance at 420 nm (A<sub>420</sub>) of



0.0045 with a 1 cm pathlength; thus, an absorbance of 1 at 420 nm represents 222 nmole ONP/mL, or 378 nmole/1.7 mL since the total volume of supernatant being analyzed is 1.7 mL. Hence, Units are calculated as follows:

5

$$U = \frac{A_{420}}{t(\text{min})} \times 378$$

The following part of the description are preferred embodiments 1 to 30 presented in the format of claims.

0183070

1. A yeast cell of the genus *Pichia* as a host capable of being transformed with recombinant DNA material; wherein said host is defective in at least one biosynthetic pathway.

2. A yeast cell in accordance with claim 1 wherein said host is defective in at least one amino acid biosynthetic pathway.

3. A yeast cell in accordance with claim 1 wherein said yeast is a member of the species *Pichia pastoris*.

4. A yeast cell in accordance with claim 2 wherein said yeast cell is defective in the histidine biosynthetic pathway.

5. A yeast cell in accordance with claim 4 wherein said histidine biosynthetic pathway is defective in histidinol dehydrogenase activity.

6. A yeast cell in accordance with claim 5 wherein said yeast cell is *Pichia pastoris* NRRL Y-15851 (GS115).

7. A yeast cell in accordance with claim 1 wherein said recombinant DNA material comprises a functional gene which complements the defect in the biosynthetic pathway in which the host is defective.

8. A yeast cell in accordance with claim 7 wherein said functional gene is selected from the group consisting of the

*Pichia* HIS4 gene, and

5

*Saccharomyces* HIS4 gene.

9. A process for transforming a host yeast strain of the genus *Pichia*, said process comprising:

(a) contacting the host yeast strain with a sulfhydryl group reducing agent;

5

(b) contacting the product cells of step (a) with a cell wall degrading reagent under conditions suitable for the formation and maintenance of spheroplasts;

0183970

(c) contacting the spheroplasts generated in step (b) with recombinant DNA material under conditions suitable for transformation; and

(d) treating the product of step (c) under cell wall regenerating conditions.

10. A process in accordance with claim 9 wherein said sulfhydryl group reducing agent is dithiothreitol.

11. A process in accordance with claim 9 wherein said cell wall degrading reagent is Zymolyase.

12. A process in accordance with claim 9 wherein said conditions suitable for the formation of spheroplasts comprise:

(i) 10-100 µg of cell wall degrading reagent per 10 mL of cell suspension; wherein said cell suspension is prepared by suspending exponentially growing cells in SCE buffer;

(ii) maintained at 25-35°C;

(iii) for 15-60 minutes.

13. A process in accordance with claim 9 wherein said host yeast strain is defective in at least one biosynthetic pathway.

14. A process in accordance with claim 13 wherein said host yeast strain is defective in at least one amino acid biosynthetic pathway.

15. A process in accordance with claim 14 wherein said host yeast strain is defective in the histidine biosynthetic pathway.

16. A process in accordance with claim 15 wherein said histidine biosynthetic pathway is defective at the gene encoding histidinol dehydrogenase.

17. A process in accordance with claim 16 wherein said host yeast strain is *Pichia pastoris* NRRL Y-15851 (GS115).

18. A process in accordance with claim 9 wherein said contacting conditions comprise:

(i) 2-10 volumes of  $\text{CaCl}_2$ -polyethylene glycol solution per volume of spheroplast-containing suspension;

5 (ii) maintained at 20-30°C;

(iii) for 5-30 minutes.

19. A process in accordance with claim 9 wherein said cell wall regenerating conditions comprise:

(i) adding transformed spheroplasts to regeneration agar, wherein said regeneration agar comprises:

5 about 1 M sorbitol,

about 0.1 M dextrose,

about 7 g/L yeast nitrogen base, and

about 3% agar;

(ii) maintained at 25-35°C;

10 (iii) for about 3-10 days.

20. A process in accordance with claim 13 wherein said recombinant DNA material comprises a functional gene which complements the defect in the biosynthetic pathway in which the host yeast strain is defective.

21. A process in accordance with claim 16 wherein said recombinant DNA material comprises a histidinol dehydrogenase encoding gene.

22. A process in accordance with claim 20 wherein said recombinant DNA material is plasmid pYA2.

23. A process in accordance with claim 20 wherein said recombinant DNA material is plasmid pYA4.

24. A process in accordance with claim 20 wherein said recombinant DNA material is plasmid pYJ30.

25. A process in accordance with claim 20 wherein said recombinant DNA material is plasmid pYJ32.

26. A process in accordance with claim 9 further comprising:

(e) growing the product cells of step (d) under selective growth conditions.

27. A process in accordance with claim 21 further comprising:

(e) growing the product cells of step (d) under selective growth conditions; wherein said selective growth  
5 conditions comprise growth on yeast minimal medium without added histidine.

28. A method for the isolation of functional genes and other functional DNA sequences from yeast strains of the genus *Pichia*, said method comprising:

(a) preparing a library by treating *Pichia*  
5 chromosomal DNA with an appropriate restriction enzyme to give *Pichia* DNA fragments and cloning said fragments into a *Pichia pastoris*-*Escherichia coli* shuttle vector;

(b) transforming a host *Pichia pastoris* strain which is defective in at least one biosynthetic pathway with  
10 said library;

(c) selecting for transformed strains;

(d) growing the transformed strains selected in step (c) under selective growth conditions; wherein said selective growth conditions comprise media containing all  
15 required nutrients for the growth of yeast absent the nutrient required by the non-transformed defective host strain for growth;

(e) isolating plasmid DNA from the transformed strains; and

20 (f) recovering *Pichia* DNA inserts from the plasmid DNA.

29. A method in accordance with claim 28 wherein said host *Pichia pastoris* strain is defective in an amino acid biosynthetic pathway.

30. A method in accordance with claim 29 wherein said host strain is *Pichia pastoris* NRRL Y-15851 (GS115).

PATENT- UND RECHTSANWÄLTE  
BARDEHLE · PAGENBERG · DOST · ALTENBURG · FROHWITTER  
& PARTNER

...0183070

RECHTSANWÄLTE

JOCHEN PAGENBERG DR. JUR. LL. M. HARVARD\*\*  
BERNHARD FROHWITTER DIPL.-ING\*\*  
GÜNTER FRHR. V. GRAVENREUTH DIPL.-ING (FH)\*  
JÜRGEN KROHER DR. JUR. LL. M. QUEEN'S UNIV.\*

PATENTANWÄLTE · EUROPEAN PATENT ATTORNEYS

HEINZ BARDEHLE DIPL.-ING  
WOLFGANG A. DOST DR., DIPL.-CHEM.  
UDO W. ALTENBURG DIPL.-PHYS  
BERNHARD H. GEISSLER DIPL.-PHYS  
DR. JUR. MCLUGWU RECHTSANWALT · US ATTORNEY AT LAW\*\*\*

POSTFACH 860620 8000 MÜNCHEN 86

TELEFON (089) 980361

TELEX 522791 pad d

TELEFAX (089) 989763

HYPOBANK MUC 6860130600 (BLZ 70020001)

PGA MUC 38737-808 (BLZ 70010080)

BÜRO GALILEIPLATZ 1, 8000 MÜNCHEN 80

DATUM October 29, 1985  
31 724-EP  
D/la

C l a i m s

- 1
1. A yeast cell of the genus *Pichia* as a host capable of being transformed with recombinant DNA material; wherein said host is defective in at least one biosynthetic pathway.
- 5
2. The yeast cell of claim 1 characterized in that said host is defective in at least one amino acid biosynthetic pathway; in particular wherein said yeast is a member of the species *Pichia pastoris*; in particular wherein said yeast
- 10
- cell is defective in the histidine biosynthetic pathway; in particular wherein said histidine biosynthetic pathway is defective in histidinol dehydrogenase activity; in particular wherein said yeast cell is *Pichia pastoris* NRRL Y-15851 (GS115).
- 15
3. The yeast cell of claim 1 characterized in that said recombinant DNA material comprises a functional gene which complements the defect in the biosynthetic pathway in which the host is defective; in particular wherein said
- 20
- functional gene is selected from the group
- Pichia* HIS4 gene, and  
*Saccharomyces* HIS4 gene.

- 1 4. A process for transforming a host yeast strain of the  
genus *Pichia*, said process comprising:
- (a) contacting the host yeast strain with a sulfhydryl  
group reducing agent;
- 5 (b) contacting the product cells of step (a) with a  
cell wall degrading reagent under conditions suit-  
able for the formation and maintenance of spherop-  
plasts;
- (c) contacting the spheroplasts generated in step (b)  
10 with recombinant DNA material under conditions  
suitable for transformation; and
- (d) treating the product of step (c) under cell wall  
regenerating conditions; . . . . .  
in particular wherein said sulfhydryl group reducing  
15 agent is dithiothreitol; in particular wherein said  
cell wall degrading reagent is Zymolyase; in par-  
ticular wherein said conditions suitable for the  
formation of spheroplasts comprise:
- (i) 10-100  $\mu$ g of cell wall degrading reagent per  
20 10 mL of cell suspension; wherein said cell  
suspension is prepared by suspending exponential-  
ly growing cells in SCE buffer;
- (ii) maintained at 25-35°C;
- (iii) for 15-60 minutes.
- 25
5. The process of claim 4 characterized in that said host  
yeast strain is defective in at least one biosynthetic  
pathway.
- 30 6. The process of claim 5 characterized in that said host  
yeast strain is defective in at least one amino acid  
biosynthetic pathway; in particular wherein said host  
yeast strain is defective in the histidine biosynthetic  
pathway; in particular wherein said histidine biosyn-  
35 thetic pathway is defective at the gene encoding histi-  
dinol dehydrogenase; in particular wherein said host  
yeast strain is *Pichia pastoris* NRRL Y-15851 (GS115).

- 1 7. The process of claim 4 characterized in that said con-  
tacting conditions comprise:  
    (i) 2-10 volumes of  $\text{CaCl}_2$ -polyethylene glycol solution  
        per volume of spheroplast-containing suspension;  
5     (ii) maintained at 20-30°C;  
    (iii) for 5-30 minutes;  
in particular wherein said cell wall regenerating conditions comprise:  
    (i) adding transformed spheroplasts to regenera-  
        tion agar, wherein said regeneration agar com-  
10     prises:  
        about 1 M sorbitol,  
        about 0.1 M dextrose,  
        about 7 g/L yeast nitrogen base, and  
        about 3% agar;  
15     (ii) maintained at 25-35°C;  
    (iii) for about 3-10 days.
- 20 8. The process of claim 5 characterized in that said re-  
combinant DNA material comprises a functional gene  
which complements the defect in the biosynthetic pathway  
in which the host yeast strain is defective; in parti-  
cular wherein said recombinant DNA material comprises  
a histidinol dehydrogenase encoding gene; in particular  
wherein said recombinant DNA material is plasmid pYA2;  
25 in particular wherein said recombinant DNA material is  
plasmid pYA4; in particular wherein said recombinant  
DNA material is plasmid pYJ30; in particular wherein  
said recombinant DNA material is plasmid pYJ32.
- 30 9. The process of claim 4 further comprising:  
    (e) growing the product cells of step (d) under selective  
        growth conditions; in particular further comprising:  
    (e) growing the product cells of step (d) under selec-  
        tive growth conditions; wherein said selective growth  
35     conditions comprise growth on yeast minimal medium  
        without added histidine.
10. A method for the isolation of functional genes and other



- 1 functional DNA sequences from yeast strains of the  
genus *Pichia*, said method comprising:
- 5 (a) preparing a library by treating *Pichia* chromosomal  
DNA with an appropriate restriction enzyme to give  
*Pichia* DNA fragments and cloning said fragments into  
a *Pichia pastoris*-*Escherichia coli* shuttle vector;
- (b) transforming a host *Pichia pastoris* strain which is  
defective in at least one biosynthetic pathway with  
said library;
- 10 (c) selecting for transformed strains;
- (d) growing the transformed strains selected in step (c)  
under selective growth conditions; wherein said  
selective growth conditions comprise media contain-  
ing all required nutrients for the growth of yeast  
15 absent the nutrient required by the non-transformed  
defective host strain for growth;
- (e) isolating plasmid DNA from the transformed strains;  
and
- (f) recovering *Pichia* DNA inserts from the plasmid DNA;  
20 in particular wherein said host *Pichia pastoris*  
strain is defective in an amino acid biosynthetic  
pathway; in particular wherein said host strain is  
*Pichia pastoris* NRRL Y-15851 (GS115).

25

30

35

1/6




FIG. 1

2/6




FIG. 2

3/6




FIG. 3

4/6




FIG. 4

5/6




FIG. 5

6/6




FIG. 6



**DECLARATION PURSUANT TO RULE 28, PARAGRAPH 4,  
OF THE EUROPEAN PATENT CONVENTION**

The applicant has informed the European Patent Office that, until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, the availability of the micro-organism(s) identified below, referred to in paragraph 3 of Rule 28 of the European Patent Convention, shall be effected only by the issue of a sample to an expert.

**IDENTIFICATION OF THE MICRO-ORGANISMS**

Accession numbers of the deposits:

NRRL Number

Y-15851  
Y-15853  
B-15862  
B-15874  
B-15890  
B-15891



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**